로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |Claudin 18.2 Hot |FMC 63 Ab  |FcRn
0
장바구니가 비어 있습니다
내 장바구니
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: 홈 > DDC

DDC

요약

Name:Aromatic-L-amino-acid decarboxylase
Target Synonym:EC:4.1.1.28,EC 4.1.1,DDC,AADC,Dopa Decarboxylase (Aromatic L-Amino Acid Decarboxylase),Aromatic-L-Amino-Acid Decarboxylase,Aromatic L-Amino Acid Decarboxylase,EC 4.1.1.28,DOPA decarboxylase
Number of Launched Drugs:8
Number of Drugs in Clinical Trials:9
Lastest Research Phase:Approved

제품 리스트 구매

제품> 결과 필터링
제품 상태별:
제품 유형별 :
종별:
태그별:
결합물별:
제품번호 종 제품 설명 구조 순도 특징
DDC-H55H6 Human Human DDC / Dopa Decarboxilase Protein, His Tag
DDC-H55H6-structure

Synonym Name

Aromatic-L-amino-acid decarboxylase,Dopa decarboxilase

Background

Dopa decarboxilase (DDC), also known as aromatic amino acid decarboxylase, is a group II decarboxylase. The enzyme catalyzes the decarboxylation of aromatic L-amino acids to produce the corresponding amines. DDC produces the neurotransmitters dopamine and serotonin from L-Dopa and L-5-hydroxytryptophan, respectively.  DDC inhibitors is in clinical use to treat Parkinson's disease(PD), usually co-administrated with L-DOPA. DDC would block peripheral conversion to dopamine and allow a greater percentage of L-DOPA to reach the brain, causing an increase in brain dopamine levels, and reducing the side effects of dopamine-rich blood.

Clinical and Translational Updates

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Levodopa/Benserazide Hydrochloride Approved F. Hoffmann-La Roche Ltd Madopar Switzerland Parkinson Disease F. Hoffmann-La Roche Ltd 1973-06-27 Parkinson Disease Details
Eladocagene exuparvovec PTC-AADC Approved National Taiwan University, Ptc Therapeutics Inc Upstaza EU Amino Acid Metabolism, Inborn Errors Ptc Therapeutics International Ltd 2022-07-18 Aromatic amino acid decarboxylase deficiency; Amino Acid Metabolism, Inborn Errors Details
Levodopa/Carbidopa IPX-066; ABT-SLV-187; ND-0680; ND-0612L; AP-CD/LD; ND-0612; IPX-054; ABT-SLV187; IPX-203; CP-012; AP-09004; DM-1992; AP-CDLD; TPI-926; ND-0612H; PW-4153; LCIG; JM-012; SOL-707; INP-107(POD™ carbidopa/levodopa) Approved Merck Sharp & Dohme Corp Numient, Menesit, Duodopa, Vadova, Sinemet, Rytary, Isicom, Duopa, Flexilev, Nacom (imciromab), Nacom retard, Parcopa, DopaFuse, Patrome United States Parkinson Disease; Parkinson Disease, Secondary; Parkinson Disease, Postencephalitic Merck & Co Inc 1975-05-02 Albinism, Oculocutaneous; Diabetes Mellitus; Amyotrophic Lateral Sclerosis; Diabetic Retinopathy; Albinism; Cocaine-Related Disorders; Amblyopia; Depressive Disorder, Treatment-Resistant; Cognitive Dysfunction; Motor Neuron Disease; Aphasia, Broca; Parkinson Disease; Stroke; Parkinson Disease, Postencephalitic; Depression; Parkinson Disease, Secondary; Gait Apraxia Details
Benserazide Hydrochloride Ro-4-4602 Approved Mainland China Parkinson Disease; Dyskinesias Shanghai Yishengyuan Pharmaceutical Co Ltd 1995-01-01 beta-Thalassemia; Dyskinesias; Parkinson Disease; Anemia, Sickle Cell Details
Foslevodopa/Foscarbidopa ABBV-951 Approved Abbvie Inc VYALEV, Vyalev, Duodopa, Produodopa Romania, Belgium, Cyprus Parkinson Disease Abbvie Deutschland Gmbh & Co Kg, Abbvie Sa, Abbvie Inc Parkinson Disease Details
Carbidopa/Entacapone/Levodopa ELC-200; ODM-101 Approved Orion Pharma Stalevo, LECIGon, Trigel, LECIGel, 达灵复 United States Parkinson Disease Orion Pharma A/S 2003-06-11 Parkinson Disease Details
Carbidopa MK-486 Approved Lodosyn United States Parkinson Disease Aton 1977-04-25 Postural Orthostatic Tachycardia Syndrome; Parkinson Disease; Orthostatic Intolerance Details
Carbidopa/Melevodopa V-1512; GT-1512; CHF-1512; CNP-1512 Approved Chiesi Farmaceutici SPA Sirio Italy Parkinson Disease null 2003-01-01 Parkinson Disease Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Buspirone/Carbidopa/Levodopa Phase 2 Clinical Universite Laval Spinal Cord Injuries; Multiple Sclerosis Details
Levodopa/Carbidopa controlled release tablets-night(WD Pharmaceutical) WD-1905 Phase 2 Clinical Shanghai WD Pharmaceutical Co Ltd Parkinsonian Disorders Details
Levodopa/Carbidopa controlled release tablets(WD Pharmaceutical) WD-1603 Phase 2 Clinical Shanghai WD Pharmaceutical Co Ltd Parkinsonian Disorders Details
Levodopa/Carbidopa (Hengrui Medicine) HRG-2010 Phase 2 Clinical Jiangsu Hengrui Medicine Co Ltd Parkinson Disease Details
Ezaladcigene resoparvovec VY-AADC; VY-AADC01; GZ-404477; AV-201; VY-AADC02 Phase 1 Clinical University Of California, Voyager Therapeutics Inc Aromatic amino acid decarboxylase deficiency; Parkinson Disease Details
Carbidopa/oxytriptan EVX-101 Phase 1 Clinical Evecxia Therapeutics Inc Depression Details
VGN-R09 VGN-R09b; VGN-R09 Phase 1 Clinical Shanghai Vitalgen BioPharma Co Ltd Aromatic amino acid decarboxylase deficiency Details
Levodopa/Carbidopa granule(WD Pharmaceutical) WD-2010 Phase 1 Clinical Shanghai WD Pharmaceutical Co Ltd Parkinsonian Disorders Details
Levodopa/Carbidopa(WD Pharmaceutical) WD-1804 Phase 1 Clinical Shanghai WD Pharmaceutical Co Ltd Parkinsonian Disorders Details

This web search service is supported by Google Inc.

totop
Call us
우리에게 전화하세요
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
Email
이메일
order.kr@acrobiosystems.com
Fax
팩스
+1 888-377-6111
Address
주소
서울 성동구 왕십리로10길 6 서울숲비즈포레 703
회사명
아크로바이오 주식회사
사업자 등록번호
186-88-02858
대표자
CHEN YIDING
사업장주소
서울특별시 송파구 중대로12길 10-20, 1층 셀렉티드송파(가락동)
linkedin twitter facebook youtube

문의

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap